Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
PubMed 30097390 ↗Modafinil
Also known as Provigil, Modalert
The short answer. People are split on Modafinil — 50% of 936 say it helped. It is most often used for focus: 86% of 689 reports say that improved. It is well studied — 155 meta-analyses on PubMed. The most common complaint is insomnia.
From 1,613 mentions in total — the rest didn't say how it went and aren't counted.
What Modafinil does, according to users
Of the people who reported each effect, the share who said it got better.
5 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 155 meta-analyses on PubMed ↗ · 297 randomized trials ↗
Conclusion: Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu
PubMed 33085721 ↗Conclusion: High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare. Strategies for important areas of need in Lewy body dementia, such as autonomic symptoms and caregiver burden, have not been investigated, nor have the views of patients and caregivers about pharmacological strategies.
PubMed 26085043 ↗Conclusion: Prescription psychostimulants, particularly prescription amphetamines given in robust doses, have a clinically significant beneficial effect to promote abstinence in the treatment of individuals with PSUD, specifically the population with cocaine use disorder.
PubMed 32601988 ↗218 human trials on ClinicalTrials.gov test Modafinil — 150 completed, 8 recruiting now. See all on ClinicalTrials.gov ↗
- Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily Activity · Healthy, Cognition · 2026
- RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) · Long COVID, Long COVID-19 · 2026
- Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies · Narcolepsy, Hypersomnia · 2012
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Modafinil is a Schedule IV controlled substance in the US. DEA controlled-substance list ↗
The current US prescription label has no boxed warning.
2 recalls of products named for Modafinil. Most recent:
- 2014-01-29 · Class II: Labeling: Label Mixup: MODAFINIL, Tablet, 200 mg may have potentially been mislabeled as one of the following drugs: OMEGA-3-ACID ETHYL ESTERS, Capsule,… record ↗
- 2014-01-22 · Class II: Labeling:Label Mixup; MODAFINIL Tablet, 50 mg (1/2 of 100 mg Tablet) may be potentially mislabeled as SACCHAROMYCES BOULARDII LYO, Capsule, 250 mg, NDC… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
32,100 adverse-event reports mention Modafinil. Most often reported:
- Fatigue · 2,945
- Nausea · 2,248
- Drug ineffective · 2,140
- Headache · 1,871
- Fall · 1,791
- Depression · 1,617
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Modafinil E — an unlikely cause of liver injury. LiverTox entry ↗
NIH has funded 28 research projects with Modafinil in the title, $20,671,967 in total (1995–2019). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Modafinil ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“It did make me focused and alert. I was working two jobs at the time and needed every ounce of energy I could muster.”
“I started experimenting with Modafinil recently - taking 200mg a day, first thing in the morning... This stuff genuinely makes me feel superhuman.”
“I took 100mg modafinil yesterday and I worked very hard. Then I slept really well (I generally do after taking modafinil as long as I take it around 6-7am).”
“The only med that works for my ADHD plus very little side effects.”
Top discussions (5)
- I tracked my brain fog for 6 months and tested everything. Here is what actually moved the needle. ↗
- Modafinil makes me feel Superhuman ↗
- all the "soft" and "hardcore" biohacks gathered in one simplified list: ↗
- Does anybody know of any trustworthy sellers for modafinil in EU? It seems all the sites are either scams or advertising scams... quite frustrating. You can buy way worse drugs easier than this stuff these days... Smh. ↗
- Going back to college. Need stack advice please ↗
Modafinil compared
Other options for focus
Sources
- User reports: 1,613 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- US DEA ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate